natgillin/translations-raw huggingface dataset:
If stopping treatment Matever should be discontinued gradually to avoid an increase of seizures.
Ako prekidate liječenje Mateverom, prekid mora biti postupan kako bi se izbjeglo pojačanje napadaja.
Dose in children (4 to 11 years) and adolescents (12 to 17 years) weighing less than 50 kg: General dose: between 20 mg per kg bodyweight and 60 mg per kg bodyweight each day.
Doza u djece (4 do 11 godina) i adolescenata (12 do 17 godina) koji imaju manje od 50 kg: Uobičajena doza: između 20 mg na kg tjelesne težine i 60 mg na kg tjelesne težine svaki dan.
Pharmathen S.A. 6, Dervenakion str. 15351 Pallini, Attiki Greece
Pharmathen S.A. 6, Dervenakion str. 15351 Pallini, Attiki Grčka
In vitro studies show that levetiracetam affects intraneuronal Ca levels by partial inhibition of N-type
Studije in vitro pokazuju da levetiracetam utječe na razinu Ca2+ u neuronima na način da djelomično inhibira
What Matever is and what it is used for What you need to know before you are given Matever How Matever is given
Što je Matever i za što se koristi Što morate znati prije nego primite Matever Kako se Matever daje Moguće nuspojave
A dose of 20 mg/kg/day titrating to 40 mg/kg/day for infants one month to less than six months and a dose of 25 mg/kg/day titrating to 50 mg/kg/day for infants and children 6 months to less than 4 years old, was use in this study.
Doza od 20 mg/kg/dan titrirana je do 40 mg/kg/dan u dojenčadi u dobi od jednog do manje od 6 mjeseci, a doza od 25 mg/kg/dan titrirana je do 50 mg/kg/dan u dojenčadi i djece u dobi od 6 mjeseci do manje od 4 godine.
If levetiracetam has to be discontinued it is recommended to withdraw it gradually (e.g. in adults and adolescents weighing more than 50 kg: 500 mg decreases twice daily every two to four weeks; in children and adolescents weighting less than 50 kg: dose decrease should not exceed 10 mg/kg twice daily every two weeks).
Ako treba prekinuti liječenje levetiracetamom, preporučuje se postupni prekid (npr. u odraslih i adolescenata tjelesne težine veće od 50 kg: smanjenje za 500 mg dva puta na dan svaka dva do četiri tjedna; u djece i adolescenata tjelesne težine manje od 50 kg: smanjenje doze ne smije biti veće od 10 mg/kg dva puta na dan svaka dva tjedna).
500 mg tablet: quinoline yellow aluminium lake (E104) 750 mg tablet: indigo carmine aluminum lake (E132), sunset yellow FCF aluminum lake (E110) 1000 mg tablet: (no additional colourant).
500 mg tableta: quinoline yellow aluminium lake (E104) 750 mg tableta: indigo carmine aluminium lake (E132), sunset yellow FCF aluminium lake (E110) 1000 mg tableta: (nema dodatnih bojila).
For children 6 years and above, an oral solution should be used for doses under 250 mg, for doses not multiple of 250 mg when dosing recommendation is not achievable by taking multiple tablets and for patients unable to swallow tablets.
U djece od 6 godina i starije, Levetiracetam oralnu otopinu treba primijenjivati za doze ispod 250 mg, za doze koje nisu višekratnici 250 mg gdje preporučeno doziranje ne može biti postignuto uzimanjem većeg broja tableta te u bolesnika koji ne mogu gutati tablete.
Levetiracetam 1,000 mg daily did not influence the pharmacokinetics of oral contraceptives (ethinylestradiol and levonorgestrel); endocrine parameters (luteinizing hormone and progesterone) were not modified.
Oralni kontraceptivi i druge farmakokinetičke interakcije Levetiracetam primijenjen u dozi od 1000 mg na dan nije utjecao na farmakokinetiku oralnih kontraceptiva (etinil-estradiola i levonorgestrela); endokrini pokazatelji (luteinizirajući hormon i progesteron) ostali su nepromijenjeni.
Six-month seizure freedom was achieved in 73.0 % of levetiracetam-treated patients and 72.8 % of carbamazepine-CR treated patients; the adjusted absolute difference between treatments was 0.2% (95 % CI: -7.8 8.2).
73,0% bolesnika liječenih levetiracetamom i 72,8% bolesnika liječenih karbamazepinom s kontroliranim otpuštanjem (CR) bilo je šest mjeseci bez napadaja: prilagođena apsolutna razlika između liječenja bila je 0,2% (95% CI: 7,8 8,2).
Tél: +33 299 979 212 Hrvatska
Panpharma Tél: +33 299 979 212
Four embryo-fetal development studies were performed in rabbits covering doses of 200, 600, 800, 1200 and 1800 mg/kg/day.
Četiri studije embrio-fetalnog razvoja provedene su u kunića s dozama od 200, 600, 800, 1200 i 1800 mg/kg/dan.
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
PODACI KOJE MORA NAJMANJE SDRŽAVATI MALO UNUTARNJE PAKIRANJE
• Lactated Ringer's injection
• injekcija Ringerove otopine s laktatom
How to take Matever
Kako uzimati Matever
The possible side effects of an overdose of Matever are sleepiness, agitation, aggression, decrease of alertness, inhibition of breathing and coma.
Moguće su nuspojave predoziranja Mateverom pospanost, uznemirenost, agresija, smanjena pozornost, smetnje disanja i koma.
Matever 250 mg film-coated tablets Matever 500 mg film-coated tablets Matever 750 mg film-coated tablets Matever 1000 mg film-coated tablets
Matever 250 mg filmom obložene tablete Matever 500 mg filmom obložene tablete Matever 750 mg filmom obložene tablete Matever 1000 mg filmom obložene tablete
Adverse reactions are presented in the order of decreasing seriousness and their frequency is defined as follows: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to<1/100); rare (≥1/10,000 to<1/1,000) and very rare (<1/10,000)
: vrlo često (≥ 1/10); često (≥ 1/100 i <1/10); manje često (≥ 1/1000 i < 1/100); rijetko (≥ 1/10 000 i < 1/1000) i vrlo rijetko (<
Matever contains sodium
Matevere sadrži natrij
6, Dervenakion str., 153 51 Pallini Attiki, Greece Tel.: +30 210 66 04 300 Fax: +30 210 66 66 749
6, Dervenakion str., 153 51 Pallini Attiki, Grčka Tel.: +30 210 66 04 300 Fax: +30 210 66 66 749
• suicide attempt and suicidal ideation, mental disorder, abnormal behaviour, hallucination, anger,
• pokušaj samoubojstva i suicidalne misli, mentalni poremećaj, poremećaj ponašanja, halucinacije,
35 infants aged less than 1 year with partial onset seizures have been exposed in placebo-control clinical studies of which only 13 were aged < 6 months.
U placebom kontroliranim kliničkim ispitivanjima lijeku je bilo izloženo 35 dojenčadi mlađe od 1 godine s parcijalnim napadajima, a samo je njih 13 bilo u dobi < 6 mjeseci.
Suicide attempt, suicidal ideation,psychotic disorder, abnormal behaviour, hallucination, anger, confusional state, panic attack, affect lability/mood swings, agitation
Pokušaj samoubojstva, suicidalne misli, psihotični poremećaj, poremećaj ponašanja, halucinacije, srditost, konfuzno stanje, napadaj panike, labilnost afekta/promjene raspoloženja, agitacija
Pallini 15351, Attiki, Greece Tel.: +30 210 66 04 300
Pallini 15351, Attiki, Grčka Tel.: +30 210 66 04 300
A large amount of post-marketing data on pregnant women exposed to levetiracetam monotherapy (more than 1,800, among which in more than 1,500 exposure occurred during the 1
Velika količina podataka nakon stavljanja lijeka u promet o trudnicama koje su bile izložene monoterapiji levetiracetamom (više od njih 1800 od kojih su više od 1500 bile izložene levetiracetamu tijekom prvog trimestra trudnoće) ne ukazuje na povećanje rizika za velike kongenitalne malformacije.
Levetiracetam has minor or moderate influence on the ability to drive and use machines.
Levetiracetam malo ili umjereno utječe na sposobnost upravljanja vozilima i rada sa strojevima
The patients were randomized to carbamazepine CR 400 -1200 mg/day or levetiracetam 1000 -3000 mg/day, the duration of the treatment was up to 121 weeks depending on the response.
Bolesnici su randomizirani za dobivanje 400 - 1200 mg karbamazepina s kontroliranim otpuštanjem (CR) na dan ili 1000 - 3000 mg levetiracetama na dan, liječenje je trajalo do 121 tjedna, ovisno o odgovoru.
Children and adolescents • Matever is not indicated in children and adolescents below 16 years on its own (monotherapy).
Djeca i adolescenti • U djece i adolescenata mlađih od 16 godina Matever se ne primjenjuje samostalno (kao monoterapija)
Rare: may affect up to 1 in 1,000 people
Rijetko: mogu se javiti u manje od 1 na 1000 ljudi
43.6 % of the levetiracetam treated patients and 19.6 % of the patients on placebo were considered as responders.
Ocijenjeno je da je na liječenje odgovorilo 43,6% bolesnika koji su uzimali levetiracetam i 19,6% onih koji su uzimali placebo.
250 mg tablet: indigo carmine aluminum lake (E132), sunset yellow FCF aluminum lake (E110),
250 mg tableta: indigo carmine aluminium lake (E132), sunset yellow FCF aluminium lake (E110),
Two embryo-fetal development (EFD) studies were performed in rats at 400, 1200 and 3600 mg/kg/day.
Provedene su dvije studije embrio-fetalnog razvoja (embryo-fetal development, EFD) u štakora s dozama od 400, 1200 i 3600 mg/kg/dan.
• as an add-on to other antiepileptic medicines to treat: partial onset seizures with or without generalisation in adults, adolescents, children and infants from one month of age myoclonic seizures (short, shock-like jerks of a muscle or group of muscles) in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy primary generalised tonic-clonic seizures (major fits, including loss of consciousness) in adults and adolescents from 12 years of age with idiopathic generalised epilepsy (the type of epilepsy that is thought to have a genetic cause).
• kao dodatna terapija uz druge antiepileptike u liječenju: djelomičnih napadaja sa sekundarnom generalizacijom ili bez nje u odraslih, adolescenata, djece i dojenčadi od prvog mjeseca života miokloničkih napadaja (kratki, iznenadni trzaji mišića ili skupine mišića) u odraslih i adolescenata starijih od navršene 12. godine života s juvenilnom miokloničkom epilepsijom primarno generaliziranih toničko-kloničkih napadaja (veliki napadaji, uključujući gubitak svijesti) u odraslih i adolescenata od navršene 12. godine života s idiopatskom generaliziranom epilepsijom (oblik epilepsije za koji se smatra da je genetski uvjetovan).
Sodium acetate trihydrate Glacial acetic acid Sodium chloride Water for injections
6.1 Popis pomoćnih tvari natrijev acetat trihidrat acetatna kiselina, ledena natrijev klorid voda za injekcije
Matever 1000 mg tablets contain lactose
Matever 1000 mg tablete sadrži laktozu
Matever 100 mg/ml concentrate for solution for infusion levetiracetam
Matever 100 mg/ml koncentrat za otopinu za infuziju levetiracetam
Matever 100 mg/ml concentrate for solution for infusion
Matever 100 mg/ml koncentrat za otopinu za infuziju
• Dextrose 5 % injection
• injekcija 5% glukoze
CLcr (ml/min)= ----------------------------------------- (x 0.85 for women) 72 x serum creatinine (mg/dl)
[140 - dob (godine)] x težina (kg) CLcr (ml/min) = --------------------------------------------- (x 0,85 za žene) 72 x kreatinin u serumu (mg/dl)
As with all antiepileptic medicinal products, sudden discontinuation of levetiracetam should be avoided as this may lead to breakthrough seizures that could have serious consequences for the woman and the unborn child. Monotherapy should be preferred whenever possible because therapy with multiple antiepileptic medicinal products AEDs could be associated with a higher risk of congenital malformations than monotherapy, depending on the associated antiepileptics.
Poželjna je monoterapija kad god je to moguće jer bi terapija kombinacijama antiepileptika mogla biti povezana s većim rizikom od kongenitalnih malformacija u odnosu na monoterapiju, ovisno o dotičnim antiepilepticima.
CLcr (ml/min) = ----------------------------------------- (x 0.85 for women) 72 x serum creatinine (mg/dl)
[140 - dob (godine)] x težina (kg) CLcr (ml/min) = ----------------------------------------------- (x 0,85 za žene) 72 x kreatinin u serumu (mg/dl)
Then CLcr is adjusted for body surface area (BSA) as follows:
Potom se klirens kreatinina prilagodi za površinu tijela (PT) prema sljedećem: CLcr (ml/min)
In paediatric patients (4 to 16 years of age), levetiracetam efficacy was established in a double-blind, placebo-controlled study, which included 198 patients and had a treatment duration of 14 weeks.
U pedijatrijskih bolesnika (4 do 16 godina života) djelotvornost levetiracetama dokazana je u dvostruko slijepoj i placebom kontroliranoj studiji koja je trajala 14 dana i uključivala 198 bolesnika.
Creatinine clearance (ml/min/1.73m
Klirens kreatinina (ml/min/1,73m2)
Česká republika ARDEZ Pharma, spol.
Česká republika ARDEZ Pharma, spol. s.r.o.
Pancytopenia neutropenia, agranulocytosis
Pancitopenija neutropenija, agranulocitoza
• in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with Idiopathic Generalised Epilepsy.
• u liječenju primarno generaliziranih toničko-kloničkih napadaja u odraslih i adolescenata od navršene 12. godine života s idiopatskom generaliziranom epilepsijom.
• Dose in adults and adolescents (12 to 17 years) weighing 50 kg or more: General dose: between 1,000 mg and 3,000 mg each day.
• Doza u odraslih i adolescenata (12 do 17 godina) koji imaju 50 kg ili više: Uobičajena doza: između 1000 mg i 3000 mg svaki dan.
The requirements for submission of PSURs for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.
• Periodička izvješća o neškodljivosti (PSUR-evi) Zahtjevi za podnošenje PSUE-eva za ovaj lijek definirani su u referentnom popisu datuma EU (EURD popis) predviđenom člankom 107.c stavkom 7.
Coating agent (orange) consisting of: Hypromellose (E464) Indigo carmine aluminum lake (E132) Sunset yellow FCF aluminum lake (E110) Iron oxide red (E172) Macrogol/PEG 4000
Sredstvo za oblaganje (narančasta) se sastoji od: hipromeloza (E464) bojilo indigo carmine aluminum lake (E132) bojilo sunset yellow FCF aluminium lake (E110) željezov oksid, crveni (E172) makrogol/PEG 4000 titanijev dioksid (E171)
The intravenous formulation is an alternative to your oral administration.
Intravenski oblik predstavlja drugu mogućnost Vašoj primjeni kroz usta.
Contains sunset yellow FCF aluminum lake (E110).
Sadrži bojilo sunset yellow FCF aluminium lake (E110).
Each ml of solution for infusion contains 100 mg of levetiracetam.
Jedan ml otopine za infuziju sadrži 100 mg levetiracetama.
Slovenská republika ARDEZ Pharma, spol.
Slovenská republika ARDEZ Pharma, spol. s.r.o.
Dose in adults and adolescents (12 to 17 years) weighing 50 kg or more: General dose: between 1,000 mg and 3,000 mg each day.
Doza u odraslih i adolescenata (12 do 17 godina) koji imaju 50 kg ili više: Uobičajena doza: između 1000 mg i 3000 mg svaki dan.
The NOAEL was ≥ 1800 mg/kg/day for the F0 females, and for the survival, growth and development of the F1 offspring up to weaning (x 6 the MRHD on a mg/m basis).
NOAEL je iznosila ≥ 1800 mg/kg/dan za F0 ženke, te za preživljenje, rast i razvoj za F1 potomstvo do odbića (6-erostruka vrijednost najveće preporučene doze za čovjeka izražena u mg/m2).
Matever is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalisation in adults and adolescents from 16 years of age with newly diagnosed epilepsy.
Matever je indiciran kao monoterapija u liječenju parcijalnih napadaja sa sekundarnom generalizacijom ili bez nje u odraslih i adolescenata od 16. godine života s novodijagnosticiranom epilepsijom.
Matever is for intravenous use.
Matever se daje u venu.
Creatinine clearance (ml/min/1.73 m
Klirens kreatinina (ml/min/1,73m
Each ml contains 3.81 mg sodium.
Pomoćna tvar s poznatim učinkom Jedan ml sadrži 3,81 mg natrija.
• skin rash, which may form blisters and looks like small targets (central dark spots surrounded by a paler area, with a dark ring around the edge) (erythema multiforme), a widespread rash with blisters and peeling skin, particularly around the mouth, nose, eyes and genitals (StevensJohnson syndrome), and a more severe form causing skin peeling in more than 30% of the body surface (toxic epidermal necrolysis);
jako rasprostranjen osip s mjehurićima i kožom koja se ljušti, osobito oko usta, nosa, očiju i genitalija (Stevens-Johnsonov sindrom), i mnogo teži oblik koji uzrokuje ljuštenje kože na više od 30% površine tijela (toksična epidermalna nekroliza);
Neonatal and juvenile animal studies in rats and dogs demonstrated that there were no adverse reactions seen in any of the standard developmental or maturation endpoints at doses up to 1800 mg/kg/day (x 6-17 the MRHD on a mg/m2 basis)
Neonatalne i juvenilne studije na štakorima i psima pokazale su da nema nuspojava u uobičajenim mjerama ishoda razvoja ili sazrijevanja kod primjene doza do 1800 mg/kg/dan (6-erostruka do 17erostruka vrijednost najveće preporučene doze za čovjeka izražena u mg/m2).
Matever 1000 mg film-coated tablets contain lactose.
Matever 1000 mg filmom obložene tablete sadrže laktozu.
Each film-coated tablet contains 0.08 mg sunset yellow FCF aluminum lake (E110).
Jedna filmom obložena tableta sadrži 0,08 mg bojila sunset yellow FCF aluminium lake (E110).
Serum Creatinine (mg/dl) ks= 0.55 in Children to less than 13 years and in adolescent female; ks= 0.7 in adolescent male
ks = 0,55 za djecu mlađu od 13 godina i za adolescente ženskog spola; ks = 0,7 za adolescente muškog spola
Film-coating: hypromellose (E464), titanium dioxide (E171), hydroxypropyl cellulose (E463), propylene glycol (E1520), sorbic acid (E200), sorbitan monooleate (E494), vanillin, colourants*.
Film-ovojnica: hipromeloza (E464), titanijev dioksid (E171), hidroksipropilceluloza (E463), propilenglikol (E1520), quinoline yellow aluminium lake (E104), sorbatna kiselina (E200), sorbitanmonooleat (E494), vanilin bojila*.
(1)A 750 mg loading dose is recommended on the first day of treatment with levetiracetam.
(1) Prvog dana liječenja levetiracetamom preporučuje se udarna doza od 750 mg.
With continued long-term treatment, 28.6 % of the patients were free of myoclonic seizures for at least 6 months and 21.0 % were free of myoclonic seizures for at least 1 year.
S nastavkom dugotrajnog liječenja 28,6% bolesnika bilo je barem 6 mjeseci i 21,0% barem 1 godinu bez miokloničkih napadaja.
Each film-coated tablet contains 0.0025 mg sunset yellow FCF aluminum lake (E110).
Jedna filmom obložena tableta sadrži 0,0025 mg bojila sunset yellow FCF aluminium lake (E110).
• in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy.
• u liječenju miokloničkih napadaja u odraslih i adolescenata od navršene 12. godine života s juvenilnom miokloničkom epilepsijom.
The CLcr in ml/min/1.73 m may be estimated from serum creatinine (mg/dl) determination, for young adolescents, children and infants, using the following formula (Schwartz formula):
Klirens kreatinina u ml/min/1,73 m2 može se za mlade adolescente, djecu i dojenčad procijeniti iz vrijednosti serumskoga kreatinina (mg/dl) s pomoću sljedeće formule (Schwartzova formula):
The NOAEL (No Observed Adverse Effect Level) was 3600 mg/kg/day for pregnant female rats (x 12 the MRHD on a mg/m basis) and 1200 mg/kg/day for fetuses.
NOAEL (No Observed Adverse Effect Level, razina pri kojoj se ne uočava štetni učinak) za gravidne štakorice iznosila je 3600 mg/kg/dan, a za fetuse 1200 mg/kg/dan (12-erostruka vrijednost najveće preporučene doze za čovjeka izražena u mg/m2).
1500 mg 15 ml (three 5 ml vials) 100 ml
5 ml) 1500 mg 15 ml (tri bočice od 5 ml) 100 ml
Tablet core: calcium hydrogen phosphate dihydrate, cellulose microcrystalline, crospovidone type A, hydroxypropylcellulose (L).
Jezgra tablete: kalcijev hidrogenfosfat dihidrat, mikrokristalična celuloza, krospovidon tipa
One tablet of Matever 1000 mg contains 1000 mg of levetiracetam.
Jedna tableta Matevera 1000 mg sadrži 1000 mg levetiracetama.
What you need to know before you take Matever
Što morate znati prije nego počnete uzimati Matever Nemojte uzimati Matever
One tablet of Matever 750 mg contains 750 mg of levetiracetam.
Jedna tableta Matevera 750 mg sadrži 750 mg levetiracetama.
Film-coating: hypromellose (E464), iron oxide red (E172), macrogol/PEG 4000, titanium dioxide (E171), colourants*.
Film-ovojnica: hipromeloza (E464), crveni željezov oksid (E172), makrogol/PEG 4000, titanijev dioksid (E171).
• amnesia (loss of memory),memory impairment (forgetfulness), abnormal coordination/ataxia
• amnezija (gubitak pamćenja), smetnje pamćenja (zaboravljivost), poremećaj koordinacije/ataksija (poremećaj koordinacije pokreta), parestezije (trnci), smetnje u koncentraciji (gubitak koncentracije);
One tablet of Matever 500 mg contains 500 mg of levetiracetam.
Jedna tableta Matevera 500 mg sadrži 500 mg levetiracetama.
confusion, panic attack, emotional instability/mood swings, agitation;
srditost, smetenost, napadaj panike, emocionalna nestabilnost/promjene raspoloženja,
Following dialysis, a 3.5 to 7 mg/kg (0.035 to 0.07 ml/kg) supplemental dose is recommended.
(4) Nakon dijalize preporučuje se dodatna doza od 3,5 do 7 mg/kg (0,035 do 0,07 ml/kg).
One tablet of Matever 250 mg contains 250 mg of levetiracetam.
Jedna tableta Matevera 250 mg sadrži 250 mg levetiracetama.
Levetiracetam oral solution should be used for doses under 250 mg, for doses not multiple of 250 mg when dosing recommendation is not achievable by taking multiple tablets and for patients unable to swallow tablets.
(1) Za doze ispod 250 mg, za doze koje nisu višekratnici 250 mg,gdje preporučeno doziranje ne može biti postignuto uzimanjem većeg broja tableta i kod bolesnika koji ne mogu gutati tablete treba koristiti levetiracetam oralnu otopinu.
How Matever is given
Kako se Matever daje
• convulsion, balance disorder (equilibrium disorder), dizziness (sensation of unsteadiness),
• konvulzije, poremećaj ravnoteže, omaglica (osjećaj nestabilnosti), bezvoljnost (nedostatak energije i volje), tremor (nevoljno drhtanje);
Method and route of administration
Način i put primjene:
Children from 4 years and adolescents weighing less than 50 kg
Doza i učestalost primjene Djeca od 4. godine i adolescenti teški manje od 50 kg
Somnolence, agitation, aggression, depressed level of consciousness, respiratory depression and coma were observed with Matever overdoses.
Kod predoziranja Matevera primijećena je somnolencija, agitacija, agresivnost, smanjena razina svijesti, depresija disanja i koma.
• Matever is not indicated in children and adolescents below 16 years on it's own (monotherapy) Other medicines and Matever
• U djece i adolescenata mlađih od 16 godina Matever se ne primjenjuje samostalno (kao monoterapija).
Following dialysis, a 5 to 10 mg/kg (0.05 to 0.10 ml/kg) supplemental dose is recommended.
(2) Nakon dijalize preporučuje se dodatna doza od 5 do 10 mg/kg (0,05 do 0,10 ml/kg).
How to store Matever
Kako čuvati Matever
1500 mg 15 ml (three 5 ml vials)
1500 mg 15 ml (tri bočice od 5 ml)
80 film-coated tablets
80 filmom obloženih tableta
Calcium hydrogen phosphate dihydrate Microcrystalline cellulose Crospovidone type A Hydroxypropylcellulose (L)
6.1 Popis pomoćnih tvari Jezgra kalcijev hidrogenfosfat dihidrat celuloza, mikrokristalična krospovidon tipa
• as an add-on to other antiepileptic medicines to treat: partial onset seizures with or without generalisation in adults, adolescents and children from 4 years of age myoclonic seizures (short, shock-like jerks of a muscle or group of muscles) in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy.
• kao dodatna terapija uz druge antiepileptike u liječenju: djelomičnih napadaja sa sekundarnom generalizacijom ili bez nje u odraslih, adolescenata i djece od 4. godine života miokloničkih napadaja (kratki, iznenadni trzaj mišića ili skupine mišića) u odraslih i adolescenata starijih od navršene 12. godine života s juvenilnom miokloničkom epilepsijom primarno generaliziranih toničko-kloničkih napadaja (veliki napadaji, uključujući gubitak svijesti) u odraslih i adolescenata od navršene 12. godine života s idiopatskom generaliziranom epilepsijom (oblik epilepsije za koji se smatra da je genetski uvjetovan).
Matever 1000 mg: The film-coated tablets are white, oblong, biconvex.
Matever 1000 mg: Filmom obložene tablete su bijele, duguljaste, bikonveksne.
PHARMACEUTICALPARTICULARS
FARMACEUTSKI
Matever 750 mg: The film-coated tablets are pink, oblong, biconvex.
Matever 750 mg: Filmom obložene tablete su ružičaste, duguljaste, bikonveksne.